Viridian Therapeutics, Inc. (VRDN) slid over 2% Friday to $33.07 as investors appeared to consolidate gains following a period of record-breaking growth. The daily move comes just two days after the stock hit a new 52-week high of $34.08, driven by a massive quarterly earnings beat and sustained analyst optimism.
| Current Price | $33.07 |
| Daily Change | -2.10% 🔴 |
| Day Range | $32.93 – $33.94 |
| 52-Week Range | $9.90 – $34.29 |
The minor decline follows a blockbuster financial report on January 14. According to MarketBeat, Viridian reported first-quarter revenue of $70.57 million, which vastly exceeded the $16.21 million analysts had estimated.
The company also reported an earnings per share (EPS) loss of $0.34, beating the consensus estimate of an $0.82 loss by $0.48.
While the stock pulled back during Friday's session, the broader outlook for the clinical-stage biopharmaceutical company remains bullish. The stock has appreciated nearly 98% over the past year, significantly outperforming many of its biotechnology peers.
Key Takeaways
- VRDN stock fell over 2% today to $33.07 but remains near multi-year highs.
- The company recently reported a $54 million revenue beat for the first quarter.
- Analysts at UBS and Wedbush maintain price targets as high as $50, implying 63% upside.
- FDA Priority Review for veligrotug (VRDN-001) is currently on track for a mid-2026 decision.
- Viridian is outperforming the broader biotech sector, which fell over 3% on average today.
| Time Period | Price Change | Performance |
|---|---|---|
| 1 Month | +0.95% | 🟢 |
| 3 Months | +49.73% | 🟢 |
| 6 Months | +95.57% | 🟢 |
| 1 Year | +97.78% | 🟢 |
What Happened to Viridian Therapeutics (VRDN) Stock Today?
Viridian shares fluctuated between $32.93 and $33.94 during Friday’s trading session before settling at $33.07. This over 2% decline represents a modest retreat from the 52-week high reached earlier this week.
Despite the daily dip, the stock profit over the last month remains at roughly 1%, with a staggering 96% gain over the last six months.
Market data indicates that the decline was not triggered by negative company news, but rather a broader sector-wide pullback. Financial news coverage shows that the biotechnology industry average dropped by over 3% today, suggesting that VRDN’s movement was part of a larger market trend.
Why Did VRDN Dip Amidst Recent Strength?
The primary driver for the daily slide appears to be profit-taking. Investors often sell shares to lock in gains after a stock reaches a significant milestone, such as the 52-week high Viridian hit on January 14.
That rally was fueled by the company's Q1 revenue of $70.57 million, which was more than four times higher than the $16.21 million Wall Street expected.
Additionally, some investors may be reacting to a minor price target adjustment from Truist Securities earlier this month. While the firm maintained its “Buy” rating, analyst Gregory Renza lowered the price target from $41 to $40.
This 2.4% decrease was a rare outlier in a sea of recent analyst upgrades.
What Are Analysts Saying About Viridian's Future Outlook?
Despite today's movement, the analyst community remains overwhelmingly confident in Viridian’s trajectory. UBS recently initiated coverage on the stock with a “Buy” rating and a $50 price target.
This target represents a 63% upside from the stock's recent trading levels, citing the potential of the company's Thyroid Eye Disease (TED) treatment. Other major firms have also raised their expectations.
Wedbush increased its price target to $47 in December, while RBC Capital Markets moved its target to $45. According to GuruFocus, 16 analysts currently provide an average price target of $39.44, suggesting roughly 30% upside remains for the stock.
| 🟢 Bull Case | 🔴 Bear Case |
|---|---|
| • Strong Q1 beat ($70.57M Rev / -$0.34 EPS) | • Short-term profit taking at 52-week high |
| • Analysts targets up to $50 (63% upside) | • Truist PT cut from $41 to $40 |
| • FDA Priority Review for TED treatment | • Minor insider selling (Jennifer Tousignant) |
Key Catalysts: Viridian's Robust Pipeline and Regulatory Milestones
The central pillar of the bull case for VRDN is veligrotug (VRDN-001), an intravenous program currently under FDA Priority Review. The drug is being developed for TED, a market currently dominated by Amgen’s Tepezza, which generates over $2 billion in annual sales.
A potential FDA approval for veligrotug is expected by June 30, 2026. Beyond veligrotug, Viridian is advancing VRDN-003, a subcutaneous program that analysts believe could be an even larger opportunity.
Phase III data for VRDN-003 is expected in the first half of 2026, making it a critical time for investors to analyze the stock and its long-term valuation. Jefferies recently named Viridian a “Top Pick in 2026,” anticipating that these pivotal readouts will fundamentally transform the company's valuation.
Insider Activity and Institutional Confidence in VRDN
Institutional investors have demonstrated strong conviction in Viridian’s pipeline over the last several months. In October 2025, Fairmount Funds Management purchased 454,545 shares at $22.00 per share.
This transaction increased their total stake to over 3.9 million shares, valued at approximately $86.1 million. On the other hand, there has been some minor insider selling.
Jennifer Tousignant sold 2,272 shares on December 31, 2025. While such sales can sometimes raise concerns, they are small relative to the massive institutional buying seen from major funds like Millennium Management and Fairmount.
How Does VRDN Compare to Its Biotechnology Peers?
When compared to its industry peers, Viridian showed relative resilience during today's market downturn. While VRDN fell over 2%, other companies in the sector, particularly high-risk growth stocks, saw much steeper declines.
Anbio Biotechnology (NNNN) plunged nearly 8%, and RAPT Therapeutics (RAPT) fell over 6%. Viridian’s financial health also remains superior to many clinical-stage peers.
The company reports a current ratio of 11.28, indicating a very strong liquidity position that can support its ongoing clinical trials. This financial stability, combined with its nearly 98% one-year stock appreciation, keeps it at the top of the biotechnology sector.
| Company | Symbol | Daily Change | Status |
|---|---|---|---|
| Viridian Therapeutics | VRDN | -2.10% | Outperforming |
| Inhibrx Biosciences | INBX | -3.07% | Underperforming |
| Industry Average | – | -3.29% | – |
| RAPT Therapeutics | RAPT | -6.00% | Underperforming |
| Anbio Biotechnology | NNNN | -7.70% | Underperforming |
What Should Viridian Investors Watch Next?
The upcoming quarters will be critical for Viridian as it prepares for several high-stakes regulatory and clinical milestones. Investors using professional charting tools to monitor price action should keep a close eye on the Q1 and Q2 readouts for SubQ Elegrobart (VRDN-003).
These results are expected to be major catalysts that could either validate or challenge the high price targets set by Wall Street. Additionally, the company plans to introduce a long-acting TSHR antibody and advance data for its FcRn franchise in the second half of 2026.
These developments will be essential for Viridian to maintain its competitive edge against established players like Amgen.
The Bottom Line
Viridian's over 2% dip today appears to be a technical correction following a period of exceptional performance and a new 52-week high. With a massive revenue beat in the books and multiple “Buy” ratings from major institutions, the fundamental story remains strong.
However, investors must weigh this optimism against the risks of clinical trial outcomes and the challenge of entering a competitive $2 billion market. While analysts anticipate a surge toward $50, the upcoming 2026 regulatory decisions will ultimately determine if the stock can sustain its current momentum.
